IMV Presents Positive Initial Results From The MVP-S Phase 2B VITALIZE Trial
The company announced positive preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, maveropepimut-S ("MVP-S"), in combination with pembrolizumab in patients with relapsed,